Novavax Q2 Results Trail Street Expectations, Slashes FY22 Outlook By 50%

  • Novavax, Inc. NVAX reported second-quarter revenue decline of 37.6% year-over-year to $185.9 million.
  • Revenues include $78 million, comprised of $55 million of product sales from NVX-CoV2373 based on three million doses sold by Novavax and $23 million of royalties, milestone, and adjuvant sales to license partners, and Grant revenue of $108 million.
  • Research and development expenses were $290 million compared to $571 million for the comparable period in 2021.
  • EPS loss for the quarter was $(6.53), widened from $(4.75) in 2Q21.
  • NVAX held cash and cash equivalents of $1.37 billion as of June 30, 2022.
  • The company is progressing variant program with top-line clinical data for Omicron expected near the end of Q3. It intends to file for authorization of Omicron-containing vaccine with U.S. FDA Q4.
  • RelatedHere's What's Going On With Novavax Shares
  • NVAX Announced initial results of the CIC Phase 1/2 trial demonstrating robust immune response with both stand-alone influenza and CIC vaccine candidates. Phase 3 trial to evaluate efficacy on-track to be initiated in 2023.
  • FY22 Guidance, lowered: Novavax expects revenue of $2 billion to $2.3 billion (down from the prior $4 billion and $5 billion) vs. a consensus of $4.27 billion.
  • Price Action: NVAX shares are trading lower by 31.88% at $39 during the post-market session on Monday.
  • Photo by Jernej Furman via Flickr
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceTop StoriesAfter-Hours CenterMoversTrading IdeasBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!